Y-mAbs Therapeutics A/S

Clinical research is centered on high-risk neuroblastoma, with particular attention to patients who have primary refractory disease or an incomplete response after salvage treatment involving bone and bone marrow.

• Refractory neuroblastoma
• Bone marrow involvement
• Osteomedullary disease

The therapeutic focus includes antibody-based treatment strategies combined with immune-supportive approaches for difficult-to-treat pediatric solid tumors.